Formulation and evaluation of sublingual delivery of piroxicam using thermosensitive polymer with an inverted Franz diffusion cell

Case report: Use of penicillin G potassium in poloxamer 407 gel to aid in healing of an equine sublingual abscess

The use of poloxamer 407 gels have been reported in several studies to prolong the release of drugs at the injection site. Oral lesions unrelated to dental disease are rare but may result in ulceration and sequestration of bone. To date, there have been no reports on the use of penicillin G potassium poloxamer 407 gel and its effect on wound healing. The present case report describes the use of a penicillin G potassium poloxamer 407 gel for the treatment of a sublingual abscess involving the mandible in a 20 year old Arabian mare who initially presented with acute onset of dysphagia, hypersalivation, and a mass under the tongue. A presumptive diagnosis of lingual cellulitis was made, and a sublingual abscess ruptured on day 7 of hospitalization. In this case, poloxamer 407 gel was used to decrease wound contamination, protect the exposed mandible, and potentially prolong the release of penicillin G potassium into the wound.

Prilling of API/fatty acid suspensions: Screening of additives for drug release modification

Current study screened additives which could modify the drug release from prills made of an active pharmaceutical ingredient/fatty acid (API/FA) suspension, without negatively influencing the processability and/or stability of the formulation. Therefore, 11 additives (i.e. emulsifiers, pore-formers and FA-based lubricants) were added in a 20% concentration to a paracetamol/behenic acid formulation. Two additives, Kolliphor® P338 and P407 provided complete drug release in less than 1 h, as their thermoreversible gel formation resulted in a disintegration of the prills. Lower Kolliphor® P338 or P407 concentrations (2.5-10%) resulted in a complete but slower drug release in 24 h as the prills no longer disintegrated and the release mechanism was dominated by pore-formation. Prills with a robust drug release profile (i.e. independent of pH and surfactant concentration of the dissolution medium) were obtained after the addition of ≥5% Kolliphor® P338 or P407 to the FA-based formulation. Based on a 6-month stability study, it was concluded that Kolliphor® P407 was a suitable additive to modify the drug release profile of API/FA suspension-based prills when formulations were stored below 25 °C at low relative humidity.